Lumos Pharma, Inc. (LUMO) financial statements (2022 and earlier)

Company profile

Business Address 4200 MARATHON BLVD.
AUSTIN, TX 78756
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments94,80998,67990,549120,738158,708131,490195,620
Cash and cash equivalents94,80998,67990,549120,738158,708131,490195,620
Receivables12826,26482479810,5325,975 
Prepaid expense     5,9214,954
Other undisclosed current assets4,7403,5063,0465,5366,22624,5267,568
Total current assets:99,677128,44994,419127,072175,466167,912208,142
Noncurrent Assets
Operating lease, right-of-use asset  735
Nontrade receivables   140140  
Property, plant and equipment793351,6333,7275,0916,83510,400
Other undisclosed noncurrent assets556249     
Total noncurrent assets:6355842,3683,8675,2316,83510,400
TOTAL ASSETS:100,312129,03396,787130,939180,697174,747218,542
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4,7786,14210,6848,69421,72337,19213,281
Accounts payable6122444755559,25622,8833,661
Accrued liabilities4,1665,89810,1988,13912,46714,3098,761
Taxes payable  11   859
Debt  4361160232571
Deferred rent credit   92
Liability for uncertainty in income taxes  653    
Deferred revenue and credits148481988
Other undisclosed current liabilities352319447    
Total current liabilities:5,1306,46111,8278,84722,03137,90514,840
Noncurrent Liabilities
Long-term debt and lease obligation, including:205 8243111285368
Operating lease, liability205 82
Other undisclosed long-term debt and lease obligation   43111285368
Liabilities, other than long-term debt   9069981,0911,560
Deferred revenue and credits9981,0911,560
Deferred rent credit   906
Other undisclosed noncurrent liabilities5,7956,0006,0006,0006,0006,0006,000
Total noncurrent liabilities:6,2056,0006,0826,9497,1097,3767,928
Total liabilities:11,33512,46117,90915,79629,14045,28122,768
Stockholders' equity
Stockholders' equity attributable to parent, including:88,977116,57278,878115,143151,557129,174195,486
Treasury stock, value(114) (1,454)(1,417)(1,142)(853)(771)
Additional paid in capital185,429182,480413,959407,199389,786295,535276,610
Accumulated deficit(96,421)(65,991)(334,001)(291,012)(237,459)(165,508)(80,353)
Other undisclosed stockholders' equity attributable to parent8383374373372  
Other undisclosed stockholders' equity     292288
Total stockholders' equity:88,977116,57278,878115,143151,557129,466195,774
TOTAL LIABILITIES AND EQUITY:100,312129,03396,787130,939180,697174,747218,542

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues23016893612,47428,70035,76868,501
Revenue, net28,71135,76868,501
Gross profit:23016893612,47428,70035,76868,501
Operating expenses(31,577)(26,471)(46,070)(74,912)(101,592)(126,526)(102,103)
Other undisclosed operating income    11  
Operating loss:(31,347)(26,303)(45,134)(62,438)(72,881)(90,758)(33,602)
Nonoperating income (expense)2816,6672,1571,875371247(41)
Investment income, nonoperating122002,2262,029616  
Other nonoperating income (expense)2696,467(19)(102)(126)247(41)
Interest and debt expense  (50)(52)(119)397(105)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes     (397)105
Loss from continuing operations before equity method investments, income taxes:(31,066)(19,636)(43,027)(60,615)(72,629)(90,511)(33,643)
Other undisclosed income from continuing operations before income taxes  5052119  
Loss from continuing operations before income taxes:(31,066)(19,636)(42,977)(60,563)(72,510)(90,511)(33,643)
Income tax expense (benefit)63613,973(12)6,9685595,356(6,738)
Net loss attributable to parent:(30,430)(5,663)(42,989)(53,595)(71,951)(85,155)(40,381)
Preferred stock dividends and other adjustments (651)     
Net loss available to common stockholders, diluted:(30,430)(6,314)(42,989)(53,595)(71,951)(85,155)(40,381)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(30,430)(5,663)(42,989)(53,595)(71,951)(85,155)(40,381)
Comprehensive loss, net of tax, attributable to parent:(30,430)(5,663)(42,989)(53,595)(71,951)(85,155)(40,381)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: